Ascendis Pharma A/S

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Cash flows from operating activities:
Net Income ($583.2m) ($481.4m) ($378.1m) ($228.0m)
Net Income From Continuing Operations ($583.2m) ($481.4m) ($378.1m) ($228.0m)
Depreciation $677k $734k $880k $6.7m $9.4m $14.9m $17.5m $18.4m $17.2m $17.2m
Amortization $445k $444k $483k $467k $490k
Amortization Cash Flow $444k $483k $467k $490k
Amortization Of Intangibles $444k $483k $467k $490k
Depreciation Amortization Depletion $18.0m $18.9m $17.7m $17.7m
Adjustments For Deferred Tax Of Prior Periods ($4.8m) $607k $70k
Deferred Income Tax $5.4m $7.3m $4.8m $15.4m
Deferred Tax $5.4m $7.3m $4.8m $15.4m
Adjustments For Share-Based Payments $7.3m $9.7m $19.7m $37.5m $53.2m $66.8m $64.2m $66.7m $95.5m $116.2m
Share-based payment $7.3m $9.7m $19.7m $37.5m $53.2m $66.8m $64.2m $66.7m $95.5m $116.2m
Asset Impairment Charge $0 $7.8m $0 $5.3m
Earnings (Loss)es From Equity Investments $17.7m $18.4m $20.1m ($16.3m)
Additional Financial Items
Adjustments For Current Tax Of Prior Period $3.9m ($126k) $513k
Adjustments For Decrease Increase In Trade Account Receivable $777k $99k $182k
Goodwill $3.5m $3.5m $3.5m $3.5m
Payments Of Lease Liabilities Classified As Financing Activities $4.0m $4.8m $6.4m $6.4m $10.4m
Payments To Acquire Or Redeem Entitys Shares $21.6m $105.3m $0 $0 $17.4m
Proceeds From Borrowings Classified As Financing Activities $136.3m $134.2m $0
Proceeds From Disposal Or Maturity Of Availableforsale Financial Assets $263.1m $149.9m $280.5m $288.9m
Proceeds From Issuing Shares $126.0m $133.1m $216.4m $529.3m $638.8m $367.9m $0 $309.9m $0
Purchase Of Interests In Associates $10.2m $0
Repayments Of Borrowings Classified As Financing Activities $11.4m $22.0m
Net profit/(loss) for the year ($68.5m) ($123.9m) ($130.1m) ($218.0m) ($419.0m) ($383.6m) ($583.2m) ($481.4m) ($378.1m) ($228.0m)
Reversal of finance income ($7.3m) ($923k) ($24.7m) ($17.8m) ($1.8m) ($59.7m) ($52.2m) ($43.9m) ($25.6m) ($114.0m)
Reversal of finance expenses $3.1m $13.8m $127k $1.2m $80.8m $3.9m $50.5m $44.1m $100.0m $206.7m
Reversal of income taxes ($227k) ($477k) ($394k) ($234k) ($219k) ($367k) $5.4m $7.3m $4.8m $15.4m
Non-cash consideration relating to revenue ($10.5m) ($6.5m) ($3.5m) ($2.4m) ($2.5m) ($2.4m) ($27.1m) ($5.6m)
Share of (profit)/loss of associates $321k $8.1m $9.5m ($12.0m) $17.7m $18.4m $20.1m ($16.3m)
Inventories ($75.4m) ($55.3m) ($78.3m) ($86.7m) ($5.9m)
Receivables ($671k) ($183k) ($1.9m) ($2.0m) ($6.7m) ($11.5m) ($32.8m) ($118.6m) $15.6m
Prepayments $1.9m ($4.9m) ($5.5m) $4.8m ($6.4m) ($11.2m) ($6.4m) ($11.4m) $10.4m ($6.1m)
Contract liabilities ($3.0m) ($94k) $0 ($6.0m) ($495k) $5.2m $8.6m ($7.1m) ($1.2m) $131k
Trade payables, accrued expenses and other liabilities $4.7m $10.8m $8.3m $7.5m $7.9m $39.2m $45.9m $3.6m $27.0m ($10.4m)
Provisions $1.2m $6.1m $26.2m $62.0m $77.6m
Cash flows generated from/(used in) operations ($60.9m) ($96.1m) ($143.0m) ($185.0m) ($272.5m) ($419.7m) ($494.7m) ($464.3m) ($299.9m) $68.2m
Finance income received $123k $923k $4.0m $10.1m $1.3m $3.7m $8.3m $17.0m $14.4m $15.3m
Finance expenses paid ($5k) ($97k) ($127k) ($717k) ($1.5m) ($1.8m) ($9.3m) ($15.7m) ($15.2m) ($22.9m)
Investments in associates ($10.2m) $0 $0
Settlement of marketable securities $263.1m $149.9m $280.5m $288.9m $7.4m $0
Cash flows from/(used in) investing activities ($672k) ($941k) ($2.6m) ($5.2m) ($291.2m) ($110.6m) $61.7m $286.5m $6.9m ($8.5m)
Payment of principal portion of lease liabilities ($4.0m) ($4.8m) ($6.4m) ($6.4m) ($10.4m)
Repayment of borrowings ($6.4m) ($10.4m) ($11.4m) ($22.0m)
Net proceeds from borrowings $0 $503.3m $136.3m $134.2m $0
Proceeds from exercise of warrants $17.4m $26.9m $11.5m $5.2m $10.3m $30.5m $87.1m
Proceeds from follow-on public offering $126.0m $133.1m $216.4m $529.3m $638.8m $367.9m $0 $0 $309.9m $0
Costs of follow-on public offering $0 $0 $19.3m $0
Acquisitions of treasury shares, net of transactions costs ($21.6m) ($105.3m) $0 $0 ($17.4m)
Payment of withholding taxes under stock incentive programs $0 $0 ($1.8m) $0 ($11.4m)
Cash flows from/(used in) financing activities $117.5m $124.7m $203.3m $493.6m $602.6m $351.4m $396.8m $134.3m $443.9m $36.3m
Beginning Cash Position $446.3m $444.8m $392.2m $559.5m
Cash Flow From Continuing Financing Activities $396.8m $134.3m $443.9m $36.3m
Cash Flow From Continuing Investing Activities $61.7m $286.5m $6.9m ($8.5m)
Change In Inventory ($55.3m) ($78.3m) ($86.7m) ($5.9m)
Change In Other Working Capital $14.8m $19.1m $60.8m $77.7m
Change In Payables And Accrued Expense $45.9m $3.6m $27.0m ($10.4m)
Change In Prepaid Assets ($6.4m) ($11.4m) $10.4m ($6.1m)
Change In Receivables ($11.5m) ($32.8m) ($118.6m) $15.6m
Change In Working Capital ($12.5m) ($99.8m) ($107.2m) $71.0m
Changes In Cash ($37.2m) ($46.6m) $144.6m $81.7m
End Cash Position $444.8m $392.2m $559.5m $616.0m
Financing Cash Flow $396.8m $134.3m $443.9m $36.3m
Free Cash Flow ($510.2m) ($469.8m) ($307.6m) $45.4m
Gain Loss On Sale Of PPE $22k $5k ($91k) $0
Interest Received CFO $8.3m $17.0m $14.4m $15.3m
Investing Cash Flow $61.7m $286.5m $6.9m ($8.5m)
Issuance Of Capital Stock $0 $0 $309.9m $0
Net Business Purchase And Sale ($10.2m) $0 $0
Net Intangibles Purchase And Sale ($530k) $0 $0
Net PPE Purchase And Sale ($5.0m) ($2.4m) ($477k) ($8.5m)
Operating Gains Losses $17.7m $18.4m $20.0m ($16.3m)
Other Non Cash Items ($4.2m) ($2.1m) $47.3m $87.1m
Proceeds From Stock Option Exercised $5.2m $10.3m $30.5m $87.1m
Provisionand Write Offof Assets $1.2m $6.1m
Purchase Of Business ($10.2m) $0 $0
Purchase Of Intangibles ($530k) $0 $0
Purchase Of PPE $941k $2.6m $5.2m $19.9m $23.7m ($14.5m) ($2.4m) ($1.4m) ($8.5m)
Repurchase Of Capital Stock ($105.3m) $0 $0 ($17.4m)
Sale Of PPE $9.5m $51k $950k $0
Stock Based Compensation $64.2m $66.7m $95.5m $116.2m
Profit or Loss ($68.5m) ($123.9m) ($130.1m) ($218.0m) ($419.0m) ($383.6m) ($583.2m) ($481.4m) ($378.1m) ($228.0m)
Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities ($672k) ($941k) ($2.6m) ($5.2m) $5.1m $0 $0 $51k $950k $0
Capital Expenditure ($14.5m) ($2.4m) ($1.4m) ($8.5m)
Net Investment Purchase And Sale $66.7m $288.9m $7.4m $0
Purchase Of Investment ($226.0m) ($213.8m) $0 $0
Sale Of Investment $280.5m $288.9m $7.4m $0
Issuance Of Debt $503.3m $136.3m $134.2m $0
Long Term Debt Issuance $503.3m $136.3m $134.2m $0
Net Issuance Payments Of Debt $496.9m $125.8m $122.8m ($22.0m)
Net Long Term Debt Issuance $496.9m $125.8m $122.8m ($22.0m)
Long Term Debt Payments ($6.4m) ($10.4m) ($11.4m) ($22.0m)
Repayment Of Debt ($6.4m) ($10.4m) ($11.4m) ($22.0m)
Common Stock Issuance $0 $0 $309.9m $0
Net Common Stock Issuance ($105.3m) $0 $309.9m ($17.4m)
Common Stock Payments ($105.3m) $0 $0 ($17.4m)
Net Other Financing Charges ($21.6m) ($1.8m) ($19.3m) ($11.4m)
Effect of exchange rate changes on balances held in foreign currencies $4.1m ($13.7m) $20.7m $7.7m ($53.5m) $38.6m $35.7m ($6.0m) $22.8m ($25.2m)
Effect Of Exchange Rate Changes $35.7m ($6.0m) $22.8m ($25.2m)
Increase/(decrease) in cash and cash equivalents $56.6m $28.7m $61.8m $312.5m $39.9m ($176.8m) ($37.2m) ($46.6m) $144.6m $81.7m
Cash and cash equivalents at January 1 $180.3m $195.4m $277.9m $598.1m $584.5m $446.3m $444.8m $392.2m $559.5m $616.0m
Change In Cash Supplemental As Reported ($37.2m) ($46.6m) $144.6m $81.7m
Interest Paid Classified As Financing Activities $1.3m ($9.3m) ($15.7m) ($15.2m) ($22.9m)
Income Taxes Paid Refund Classified As Operating Activities ($558k) ($153k) ($332k) $279k ($1.1m) ($152k) $3k $4.5m $5.5m $6.7m